Compare Stocks: ACRV, FULC, SABS, and CYPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.61 +2.5%	$1.89	$1.27 ▼ $3.56	$68.99M	1.96	185,759 shs	362,190 shs
CYPH Cypherpunk Technologies	$2.88 +16.6%	$2.84	$0.40 ▼ $4.19	$310.36M	1.09	12.99 million shs	21.80 million shs
FULC Fulcrum Therapeutics	$3.70 +0.5%	$3.75	$2.83 ▼ $15.74	$282.61M	2.82	1.38 million shs	891,762 shs
SABS SAB Biotherapeutics	$3.03 +3.1%	$3.19	$2.44 ▼ $5.15	$275.69M	0.67	626,988 shs	300,599 shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+2.55%	-3.01%	-14.36%	-6.94%	-20.69%
CYPH Cypherpunk Technologies	+16.60%	-3.36%	-5.57%	+318.24%	+601.93%
FULC Fulcrum Therapeutics	+0.54%	-0.27%	+0.82%	-4.88%	-52.99%
SABS SAB Biotherapeutics	+3.06%	-9.55%	+5.21%	-22.31%	-4.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.61 +2.5%	$1.89	$1.27 ▼ $3.56	$68.99M	1.96	185,759 shs	362,190 shs
CYPH Cypherpunk Technologies	$2.88 +16.6%	$2.84	$0.40 ▼ $4.19	$310.36M	1.09	12.99 million shs	21.80 million shs
FULC Fulcrum Therapeutics	$3.70 +0.5%	$3.75	$2.83 ▼ $15.74	$282.61M	2.82	1.38 million shs	891,762 shs
SABS SAB Biotherapeutics	$3.03 +3.1%	$3.19	$2.44 ▼ $5.15	$275.69M	0.67	626,988 shs	300,599 shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+2.55%	-3.01%	-14.36%	-6.94%	-20.69%
CYPH Cypherpunk Technologies	+16.60%	-3.36%	-5.57%	+318.24%	+601.93%
FULC Fulcrum Therapeutics	+0.54%	-0.27%	+0.82%	-4.88%	-52.99%
SABS SAB Biotherapeutics	+3.06%	-9.55%	+5.21%	-22.31%	-4.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	2.50	Moderate Buy	$13.50	738.51% Upside
CYPH Cypherpunk Technologies	2.00	Hold	$4.90	70.14% Upside
FULC Fulcrum Therapeutics	1.75	Reduce	$8.20	121.62% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	296.04% Upside

Current Analyst Ratings Breakdown

Latest ACRV, FULC, SABS, and CYPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	FULC Fulcrum Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/9/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/24/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/17/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/10/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$1.60 ➝ $4.90
9/3/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$1.60
8/20/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$0.90 ➝ $1.60
8/17/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 11/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$3.57 per share	N/A
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$1.83 per share	N/A
FULC Fulcrum Therapeutics	$80M	3.53	N/A	N/A	$6.45 per share	0.57
SABS SAB Biotherapeutics	$1.32M	208.86	$0.34 per share	8.87	$3.18 per share	0.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$77.90M	-$1.88	N/A	N/A	N/A	N/A	-70.14%	-61.60%	11/12/2026 (Estimated)
CYPH Cypherpunk Technologies	$4.82M	$0.56	N/A	N/A	N/A	N/A	-20.76%	-19.48%	N/A
FULC Fulcrum Therapeutics	-$74.88M	-$1.21	N/A	N/A	N/A	N/A	-25.38%	-24.15%	N/A
SABS SAB Biotherapeutics	$13.27M	-$1.30	N/A	N/A	N/A	N/A	-40.70%	-36.63%	N/A

Latest ACRV, FULC, SABS, and CYPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ACRV Acrivon Therapeutics	-$0.45	N/A	N/A	N/A	$0.50 million	N/A
11/5/2026	Q3 2026	SABS SAB Biotherapeutics	-$0.2746	-$0.24	+$0.0346	-$0.24	$0.13 million	N/A
8/12/2026	Q2 2026	ACRV Acrivon Therapeutics	-$0.5022	-$0.43	+$0.0722	-$0.43	$0.39 million	N/A
8/12/2026	Q2 2026	CYPH Cypherpunk Technologies	N/A	$0.18	N/A	$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	7.99	7.99
CYPH Cypherpunk Technologies	N/A	79.19	79.19
FULC Fulcrum Therapeutics	N/A	31.35	31.35
SABS SAB Biotherapeutics	0.01	9.22	9.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
CYPH Cypherpunk Technologies	30.46%
FULC Fulcrum Therapeutics	89.83%
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	10.50%
CYPH Cypherpunk Technologies	3.50%
FULC Fulcrum Therapeutics	7.30%
SABS SAB Biotherapeutics	7.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	76	42.85 million	38.35 million	Not Optionable
CYPH Cypherpunk Technologies	40	107.76 million	103.99 million	Optionable
FULC Fulcrum Therapeutics	55	76.38 million	70.81 million	Optionable
SABS SAB Biotherapeutics	86	90.99 million	84.26 million	Optionable

ACRV, FULC, SABS, and CYPH Headlines

Recent News About These Companies

What SAB Biotherapeutics (SABS) Said on Its Q3 Earnings Call

November 6 at 6:13 PM | marketbeat.com

SAB Biotherapeutics (SABS) Q3 2026 Earnings Call Transcript

November 6 at 4:29 PM | fool.com

SAB Biotherapeutics, Inc. (SABS) Q3 2026 Earnings Call Transcript

November 6 at 2:00 PM | seekingalpha.com

SAB Biotherapeutics (NASDAQ:SABS) Announces Quarterly Earnings Results

November 5 at 12:40 AM | marketbeat.com

SAB Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 5 at 3:22 PM | marketscreener.comM

SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights

November 5 at 7:30 AM | globenewswire.com

SAB Biotherapeutics (NASDAQ:SABS) Stock Price Crosses Above 50-Day Moving Average - Should You Sell?

October 31, 2026 | marketbeat.com

SAB Biotherapeutics (SABS) Expected to Post Earnings on Thursday

October 31, 2026 | americanbankingnews.com

SAB Biotherapeutics (SABS) Expected to Release Quarterly Earnings on Thursday

October 31, 2026 | marketbeat.com

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET

October 29, 2026 | globenewswire.com

SAB Biotherapeutics, Inc. (SABS) - What Are Investment Firms Saying About This Stock?

October 25, 2026 | marketbeat.com

SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform

October 23, 2026 | marketbeat.com

SAB Biotherapeutics Says SAB-142 Receives FDA Fast Track Designation in Type 1 Diabetes

October 14, 2026 | finance.yahoo.com

SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

October 14, 2026 | globenewswire.com

SAB Biotherapeutics, Inc. Receives FDA Fast Track Designation For SAB-142 In Stage 3 Type 1 Diabetes

October 13, 2026 | marketscreener.comM

SAB Bio Wins FDA Fast Track Status For SAB-142 In Type 1 Diabetes; Stock Up

October 13, 2026 | rttnews.com

SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

October 13, 2026 | globenewswire.com

SAB Biotherapeutics, Inc. Announces Presentations Featuring SAB-142 Phase 1 Data At Breakthrough T1D Clinical & Research Congress

October 1, 2026 | marketscreener.comM

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

October 1, 2026 | globenewswire.com

SAB Biotherapeutics, Inc. Announces Presentations Of SAB-142 Data At The 62nd Annual Meeting Of The European Association For The Study Of Diabetes

September 22, 2026 | marketscreener.comM

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

September 22, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, FULC, SABS, and CYPH Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.61 +0.04 (+2.55%)

Closing price 11/6/2026 04:00 PM Eastern

Extended Trading

$1.61 0.00 (0.00%)

As of 11/6/2026 07:30 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Cypherpunk Technologies NASDAQ:CYPH

$2.88 +0.41 (+16.60%)

As of 11/6/2026 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Fulcrum Therapeutics NASDAQ:FULC

$3.70 +0.02 (+0.54%)

Closing price 11/6/2026 04:00 PM Eastern

Extended Trading

$3.70 0.00 (0.00%)

As of 11/6/2026 07:26 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

SAB Biotherapeutics NASDAQ:SABS

$3.03 +0.09 (+3.06%)

Closing price 11/6/2026 04:00 PM Eastern

Extended Trading

$3.05 +0.02 (+0.69%)

As of 11/6/2026 06:43 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRV, FULC, SABS, and CYPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRV, FULC, SABS, and CYPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRV, FULC, SABS, and CYPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, FULC, SABS, and CYPH Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Cypherpunk Technologies NASDAQ:CYPH

Fulcrum Therapeutics NASDAQ:FULC

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRV, FULC, SABS, and CYPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRV, FULC, SABS, and CYPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRV, FULC, SABS, and CYPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, FULC, SABS, and CYPH Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Cypherpunk Technologies NASDAQ:CYPH

Fulcrum Therapeutics NASDAQ:FULC

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools